Treatment of Complicated Staphylococcus aureus Bacteremia

JAMA Author Interviews
13/08/2025 11 min
Treatment of Complicated Staphylococcus aureus Bacteremia

Listen "Treatment of Complicated Staphylococcus aureus Bacteremia"

Descargar episodio Ver en sitio original

Episode Synopsis

Dalbavancin, a long-acting IV lipoglycopeptide, may be an option for the treatment of complicated Staphylococcus aureus bacteremia without requiring long-term IV access. Author Thomas L. Holland, MD, MSc, from Duke University School of Medicine discusses key points of the DOTS randomized clinical trial and more with JAMA Deputy Editor Preeti Malani, MD, MSJ. Related Content: Dalbavancin for Treatment of Staphylococcus aureus Bacteremia Management of Staphylococcus aureus Bacteremia

More episodes of the podcast JAMA Author Interviews

From the JAMA Network: Acetaminophen Use in Pregnancy and Risk of Autism 30/09/2025
From the JAMA Network: AI-Based Analysis for Parkinsonism 30/08/2025
From the JAMA Network: Incidence and Nature of Antidepressant Discontinuation Symptoms 05/08/2025
From the JAMA Network: GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension 28/07/2025
Life Support and Outcomes in Patients Admitted to Intensive Care Units 14/04/2025
Increases in Invasive Group A Streptococcal Infections 07/04/2025
Preventive Health Care Among Adults Eligible for Lung Cancer Screening 02/04/2025
Cardiac Arrests During Long-Distance Running: What’s Changed? 30/03/2025
Inhaled Sedation With Sevoflurane for Acute Respiratory Distress Syndrome (ARDS) 18/03/2025
New FDA Pulse Oximetry Guidance: Strengths and Weaknesses 05/03/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA